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ABSTRACT: The long-acting β2-agonist salmeterol inhibits in vitro the release of
inflammatory mediators up to 20 h. These mediators are involved in ultrasonically
nebulized distilled water (UNDW)-induced bronchoconstriction. We investigated
whether salmeterol provides prolonged protection against UNDW provocation and
whether this effect was paralleled by its bronchodilator effects.
Nineteen asthmatic patients (mean forced expiratory volume in one second (FEV1)
84.8% predicted, mean provocative concentration of histamine producing a 20%
decrease in FEV1 0.65 mg·mL-1) participated in this randomized, double-blind,
placebo-controlled crossover trial. After measuring baseline FEV1, patients inhaled
50 µg salmeterol or placebo by metered-dose inhaler. FEV1 was measured after
20 and 40 min, and UNDW provocations and FEV1 measurements were performed
after 10, 20 and 34 h.
Compared to placebo, salmeterol caused marked bronchodilatation from 20 min
up to 20 h after inhalation. Salmeterol also provided more than 20 h of protection
against UNDW provocation (still more than one doubling dose). Protection beyond
the period of bronchodilatation did not occur. Eleven subjects had a significant
reduction in provocative dose of UNDW causing a 20% fall in FEV1 (PD20,UNDW)
values between 10 and 20 h, at a time when there was still persistent bronchodi-
lation. No correlation existed between changes in FEV1 and changes in PD20,UNDW.
From the equations of regression lines between FEV1 and corresponding PD20,UNDW
values, it was calculated that only ~25% of the afforded protection was explained
by bronchodilatation.
In conclusion, a single dose of salmeterol induces both bronchodilatation and
protection independently of this bronchodilation against a physiological bron-
choconstrictor stimulus for more than 20 h.
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The long-acting β2-agonist salmeterol xinafoate has a
higher potency and much longer duration of action than
the short-acting β2-agonists such as salbutamol [1].
Unlike the short-acting β2-agonists, it has been suggest-
ed that salmeterol has some anti-inflammatory proper-
ties. In vitro data showed that salmeterol blocked mast
cell mediator release 10–35 times more potently than
salbutamol, with effects persisting for more than 20 h
[2]. Salmeterol, but not salbutamol, also had inhibitory
effects on other inflammatory cells such as eosinophils
and alveolar macrophages [3], and afforded long-last-
ing inhibition of increases in vascular permeability [4].
Despite these cellular and vascular effects, evidence that
they are of clinical relevance is still lacking. No change
in bronchial hyperresponsiveness (BHR) was reported after
6 weeks of treatment with salmeterol [5] and analysis of
bronchoalveolar lavage (BAL) cell profile has not shown
convincing evidence of an anti-inflammatory effect [6].
On the other hand, TWENTYMAN et al. [7] suggested that
salmeterol has some additional effects, i.e. preventing
the increase in BHR after allergen provocation, beyond
the time of bronchodilation. PEDERSEN et al. [8] also re-
ported that salmeterol blocked the late asthmatic resp-
onse and increase in BHR after allergen provocation.
In contrast to pharmacological stimuli such as histam-
ine and methacholine, ultrasonically nebulized distilled
water (UNDW) induces airway narrowing indirectly, by
causing the release of endogenous mediators and possi-
bly by initiating vagal reflex mechanisms [9, 10]. Chal-
lenge with UNDW may increase BHR and induce a late
asthmatic response, in the same manner as allergen expo-
sure [10]. Thus, the mechanism by which UNDW provo-
cation induces bronchoconstriction is likely to be similar
to those involved in asthma provoked by naturally occur-
ring stimuli [9]. If the above-mentioned long-lasting
cell-stabilizing effect of salmeterol were present in vivo,
this drug might be expected to afford prolonged pro-
tection against UNDW provocation.
The present study was, therefore, designed to assess
whether a single dose of salmeterol provided long-last-
ing protection against UNDW provocation and whether
or not this was caused by its bronchodilating properties.
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Materials and methods
Study design
This randomized, double-blind, placebo controlled,
crossover trial consisted of two identical 3 day study
periods, with a minimal interval of 1 week between the
start of the two periods, in order to prevent any carry-
over effect. Subjects withheld rescue medication (salbu-
tamol 100 µg by metered dose inhaler (MDI)) at least
6 h before each visit and rested for at least 15 min before
starting measurements.
On the first day, at 22.00 h, baseline forced expiratory
volume in one second (FEV1) was measured. Subsequent-
ly, study medication was administered, consisting of two
inhalations of 25 µg of salmeterol or placebo by MDI
in random order. Flow-volume curves were recorded 20
and 40 min afterwards. On the second and third day,
i.e. 10 h (at 08.00 h), 20 h (at 18.00 h), and 34 h (08.00
h the next day) after inhalation of the study medication,
FEV1 measurements and a UNDW provocation were
performed. Baseline FEV1 on the starting evening of
both periods had to be within 10%, otherwise the sec-
ond period was postponed to a later day.
Subjects
Nineteen nonsmoking asthmatic patients (6 males, 13
females) according to the criteria of the American Thoracic
Society [11], aged 16–54 (mean 28) yrs, entered the
study. Sixteen persons were atopic, defined by an ele-
vated specific immunoglobulin E or positive intracuta-
neous tests against house dust mite or two of seven other
tested common aero-allergens [12]. At study entry, FEV1
had to be ≥50% predicted, and reversibility had to be
≥15% from prebronchodilator values in response to 200
µg salbutamol by MDI. The provocative concentration
of histamine causing a 20% fall in FEV1 (PC20,H) [13]
had to be below 4 mg·mL-1 for all subjects. None had
any significant medical condition or an upper or lower
respiratory tract infection within 6 weeks before the
study. Seasonally allergic persons were not measured
during the time when exposure to such allergen was like-
ly. During the study, the subjects used only salbutamol
by MDI (100 µg) as needed to control symptoms. Anti-
inflammatory treatment (inhaled corticosteroids, nedo-
cromil sodium, and cromolyn sodium) were withheld
for at least 6 weeks preceding the study and systemic
steroids for at least 6 months. Methylxanthines were
stopped at least 48 h, anticholinergics and antihistam-
ines at least 24 h, before the start of the trial. The study
was approved by the local hospital Ethics Committee;
written informed consent was obtained from all partic-
ipants.
Methods
The bronchodilator response and reactions to UNDW
provocation were assessed by FEV1, obtained from flow-
volume curves recorded on a heated pneumotachograph
(Spiro analyser ST 250®; Fukuda Sangyo Co., Tokyo).
Baseline FEV1 was recorded from the best of three repro-
ducible values (within 5%).
The UNDW provocation test was performed accord-
ing to the method described by GROOT et al. [14]. An
ultrasonic nebulizer (Ultraneb 99, DeVilbiss, Somerset,
PA, USA) was used at a fixed output of 2.00±0.05
mL·min-1. The patient inhaled UNDW during tidal brea-
thing through a mouthpiece with tightened lips and the
nose clipped. A Wright respirometer (British Oxygen
Co., London, UK) was connected to a two-way valve
(Laerdal IV, Stavanger, Norway), placed in-between the
aerosol hose and the mouthpiece, to measure the total
volume of inhaled air. After inhalation of 20 L of ambi-
ent air through the system, doubling volumes of air with
UNDW (3, 5, 10, up to 160 L) were successively inhaled
at 5 min intervals. The response to inhaled UNDW was
assessed by FEV1 after 90 and 180 s of each dose. The
test was stopped if FEV1 dropped by at least 20% or if
160 L of air with UNDW was inhaled. Before and after
each test, the nebulizer chamber and aerosol hose were
weighted. The cumulative dose of inhaled distilled water
in mL H2O causing a 20% fall in FEV1 from post-air
values (PD20,UNDW), was calculated by linear interpo-
lation on a semilogarithmic curve.
Pretrial PC20,H was measured according to the method
of COCKROFT et al. [13]. In short, the patient inhaled
doubling doses of histamine phosphate from 0.03 to 16
mg·mL-1. The test was stopped if FEV1 fell 20% from
baseline, and a log dose-response curve was construct-
ed. The PC20,H was calculated in mg·mL-1 by linear
interpolation.
Statistical analysis
All PD20,UNDW data were log10 transformed before
analysis. FEV1 data were expressed as % pred [15]. To
calculate the treatment effect of salmeterol, differences
between values (FEV1 and PD20,UNDW) on salmeterol
and on placebo were calculated and tested at each time-
point with the Wilcoxon signed rank test. The change
in UNDW responsiveness (∆PD20,UNDW) was expressed
in doubling doses (DD), calculated as:
((logPD20,UNDW-salmeterol)-
(logPD20,UNDW-placebo))/log2
Period and carry-over effects were analysed accord-
ing to KOCH [16]. The coefficient of repeatability for
PD20,UNDW was calculated for each subject using the
two UNDW provocations in the placebo period (base-
line), at the same time of the day (08:00 h) according
to the method of BLAND and ALTMAN [17]. Correlations
between variables were performed with the Spearman
correlation test. Regression lines were compared with
analysis of variance (ANOVA) of repeated measure-
ments. For multiple comparisons, a Bonferroni correc-
tion was used. A p-value of 0.05 or less was considered
significant for one test. For multiple comparisons, this
boundary was set at 0.01. Data are reported as mean
values (SEM).
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Results
Patient characteristics are listed in table 1. Seven-
teen patients completed the study. Two persons (sub-
jects No. 2 and 8) failed to return to the laboratory for
lung function and provocation tests for the second
treatment period (both after placebo in period one) and
were withdrawn from the study. There were no period
or carry-over effects between the two study periods at
any time-point with regard to FEV1 and PD20,UNDW
data.
Baseline FEV1 and changes during study medication
Baseline FEV1 at 22.00 h on the starting day of both
periods was similar with a variation of 1.8% (range
0.3–9.7% pred).
Salmeterol caused a significant and substantial degree
of bronchodilatation versus placebo from 20 min up to
20 h after inhalation (per cent increase from baseline
after salmeterol 14.8 (2.1), 17.7 (2.3), 13.9 (3.2) and
12.7 (1.7) 1% after 20 and 40 min and 10 and 20 h,
respectively; all time-points significantly different from
placebo (p<0.001), except for 34 h (p=0.55)) (table 2).
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Table 1.  –  Characteristics of the study subjects
Subject Sex Age Atopic FEV1 Reversibility* PC20,H Medication+
No. yrs % pred % mg·mL-1
1 M 33 Yes 85.2 15.1 0.33 B
2 F 23 Yes 95.0 15.6 0.09 B
3 M 26 Yes 99.6 17.4 0.36 B
4 M 25 Yes 64.0 24.5 1.09 B
5 F 18 Yes 56.2 31.7 0.08 B, T
6 M 39 Yes 85.6 18.5 0.71 B, C
7 F 42 No 59.0 26.9 0.07 B
8 F 26 Yes 99.7 15.6 0.15 B
9 F 16 Yes 106.3 15.6 0.10 B
10 M 22 Yes 77.6 26.1 0.62 B
11 F 27 Yes 96.3 19.2 0.15 B
12 F 22 No 99.7 15.1 1.05 B
13 F 26 Yes 100.3 27.9 0.25 B
14 F 23 Yes 90.3 19.7 0.90 B
15 M 18 Yes 60.2 46.4 0.07 A,B
16 F 54 No 103.3 30.9 1.98 B
17 F 31 Yes 76.4 16.7 3.62 B
18 F 27 Yes 84.9 18.7 0.25 B, IC
19 F 26 Yes 77.3 22.5 0.54 B, C
Mean 27.6 85.1 22.3 0.65
SEM 2.1 3.7 1.8 0.20
*: reversibility to salbutamol 200 µg by metered-dose inhaler (% change from prebronchodilator value). +: therapy until 6 weeks
before participation in the study. PC20,H: provocative concentration of histamine causing a 20% fall in forced expiratory volume
in one second; A: anticholinergic; B: β2-agonist; C: cromolyn sodium; IC: inhaled corticosteroids; T: oral theophylline; M: male;
F: female.
Table 2.  –  Individual data of forced expiratory volume in one second (percentage of predicted value)
Time after inhalation
Patient 20 min 40 min 10 h 20 h 34 h
No.
Baseline SLM Placebo SLM Placebo SLM Placebo SLM Placebo SLM Placebo
l 84.5 103.1 84.3 105.6 87.2 93.1 81.1 92.8 82.8 82.8 80.6
3 106.0 115.8 104.9 119.0 108.0 113.6 106.0 113.4 116.0 98.4 103.0
4 55.1 63.2 56.6 67.3 60.9 63.8 44.1 60.7 56.4 54.3 44.6
5 54.2 64.3 56.4 67.9 53.4 46.0 38.9 64.6 55.3 57.8 60.5
6 85.0 91.0 86.4 96.2 85.8 95.1 73.1 88.4 89.9 75.2 81.2
7 49.0 53.5 50.9 53.5 51.2 59.7 50.9 66.4 50.9 52.7 50.5
9 109.4 119.4 108.0 120.2 109.1 121.7 112.8 117.1 115.7 117.1 113.4
10 76.7 95.0 73.8 98.6 77.3 95.8 71.2 99.0 80.9 88.8 66.6
11 95.6 114.5 99.6 112.3 101.8 124.3 100.9 108.0 100.6 99.0 100.3
12 94.6 100.5 94.0 107.0 82.1 98.3 70.8 108.2 79.8 63.4 73.6
13 68.8 105.5 60.0 104.3 58.3 106.1 62.9 90.9 72.3 68.8 83.0
14 94.9 111.1 94.4 111.7 100.0 111.1 90.3 111.9 102.5 100.2 92.8
15 61.2 75.4 65.1 82.5 60.6 86.0 56.5 75.2 49.8 46.2 46.4
16 87.7 118.7 80.2 123.9 81.6 102.3 89.6 104.2 89.6 84.0 86.3
17 81.2 92.6 81.8 94.2 83.4 92.9 80.8 92.3 85.0 81.5 78.2
18 90.6 98.1 83.7 97.2 86.1 100.6 78.6 94.8 83.1 82.5 54.2
19 93.8 97.3 90.2 95.8 91.4 97.0 90.2 92.9 93.5 86.1 81.4
Mean 81.7 95.2 80.6 97.5 81.1 94.5 76.4 93.0 82.6 78.7 76.3
SEM 4.4 4.9 4.3 4.8 4.5 5.1 5.1 4.2 5.0 4.7 4.9
SLM: salmeterol.
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The early morning dip seen after treatment with pla-
cebo (at 08.00 h) (mean change in FEV1 -7.2%, range
-28 to +5, compared to 22.00 h) was completely abol-
ished in all but one patient (p<0.001). The next morn-
ing (34 h after inhalation), salmeterol no longer provided
protection against a morning dip.
UNDW provocation tests
Two of the 17 persons differed in their response to
UNDW provocation from the others. Subject No. 1
appeared to be unresponsive to UNDW provocation. He
recovered very fast from the constrictor effects of UNDW
and showed a plateau in reaction of FEV1 at 80% of the
post-air values. Subject No. 10 turned out to be refrac-
tory to subsequent UNDW provocation tests. PD20,UNDW
increased at subsequent tests, and he ended totally unre-
sponsive at the third test (table 3). For these two patients,
no real treatment effect of salmeterol could be calcu-
lated, but exclusion of their data did not alter the lev-
els of significance for the major outcome variables. The
other 15 subjects demonstrated a good short-term repro-
ducibility of PD20,UNDW. The standard deviation of the
differences for baseline UNDW provocations was 0.67
DD.
In the whole group (n=17), treatment with salmeterol
resulted in protection against UNDW-induced broncho-
constriction for at least 20 h (table 3). Ten hours after
the inhalation of salmeterol, a significant increase was
observed in the PD20,UNDW of 16.7 (2.3) mL H2O as
compared with 3.3 (1.4) mL H2O after placebo (treat-
ment effect of 2.82 (0.35) DD, p<0.0001). In nine of the
17 subjects, the maximum dose of UNDW was reached.
In these patients, the total amount of mL H2O inhaled
at that time was taken for analysis, since no PD20,UNDW
could be reached after salmeterol. Twenty hours after
inhalation (at 18.00 h) there was still a significant pro-
tection for UNDW, with a PD20,UNDW of 7.0 (1.5) mL
H2O after salmeterol as compared with 3.3 (0.7) mL
H2O after placebo (treatment effect of 1.09 (0.23) DD,
p=0.0008). After 34 h (at 08.00 h) PD20,UNDW values
returned to placebo level (4.8 (1.6) mLH2O after salme-
terol as compared with 5.0 (2.0) mL H2O after placebo(treatment effect of 0.1 (0.2) DD, p=0.55)).
Relationship between UNDW provocation and airway
calibre
For each time-point, ∆PD20,UNDW was not correlat-
ed with the corresponding change in FEV1 (∆FEV1)
from placebo to salmeterol (all r<0.11, p>0.65).
Figure 1 shows the FEV1 and corresponding PD20,UNDW
values of the individual patients 10 and 20 h (fig. 1a), and
20 and 34 h (fig. 1b) after inhalation of salmeterol. From
10 to 20 h, in most individual patients and as a group,
FEV1 did not change (p=0.38), while PD20,UNDW drop-
ped significantly (p=0.002, fig. 1b). From 20 to 34 h,
both mean FEV1 and mean PD20,UNDW decreased sig-
nificantly (p<0.001 and p=0.02, respectively), but again
some individual patients showed (almost) no decrease
in FEV1, while PD20,UNDW dropped (lines appear rough-
ly vertical), while other patients exhibited a decrease in
FEV1 with no change in PD20, (lines are more or less
horizontal). Both time courses indicate that the protec-
tion afforded by salmeterol was independent from bron-
chodilation.
The slopes of the regression lines through these points
after 10 and 20, but not after 34 h on salmeterol and
placebo differed significantly from zero (p=0.001 and
p=0.03, respectively), indicating a (linear) relationship
between starting airway calibre and BHR. The slopes
between the regression lines of salmeterol in compari-
son with placebo were not different at any time-point
(all p>0.49), but again, both after 10 and 20 h, the treat-
ment effect of salmeterol was highly significant, plac-
ing the lines after salmeterol parallel at a higher level
compared to placebo (p=0.000 and p=0.002, respec-
tively). Previously, it has been shown that there is a lin-
ear relationship between FEV1 and the provocative
concentration of methacholine causing a 20% fall in
FEV1 (PC20,M) [18]. Under the assumption of a simi-
lar relationship between FEV1 and PD20,UNDW and
because the measurements on salmeterol and on place-
bo are paired, the relationship between PD20,UNDW, and
FEV1 can be describe statistically with one equation for
the regression lines at each time-point:
after 10 h: PD20,UNDW = -0.747 + 1.075  treatment +
0.035×FEV1
after 20 h: PD20,UNDW = -0.636 + 0.408 treatment +
0.028×FEV1
where treatment is assigned a value of +1 for salme-
terol and -1 for placebo.
∆PD20,UNDW is 2.8 and 1.1 DD, and ∆FEV1 is 18.4%
and 10.4%, after 10 and 20 h, respectively. It follows
from the equation that 10 h after inhaling salmeterol,
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Table 3.  –  Individual data of PD20
Time after inhalation
Patient 10 h 20 h 34 h
No. SLM Placebo# SLM Placebo SLM Placebo#
1 19.3 25.0 6.1 10.9 11.2 21.2
3 15.4 2.6 2.7 4.8 1.3 1.9
4 1.7 0.9 1.3 1.2 1.7 1.3
5 1.0 0.3 1.9 0.4 0.2 0.5
6 18.5 6.3 10.6 7.6 10.0 6.5
7 21.7 0.7 6.7 1.8 2.2 2.8
9 19.9 0.9 4.7 1.0 2.7 1.3
10 30.1 1.7 25.6 6.1 27.3 31.2
11 12.2 3.4 7.7 3.0 2.1 3.8
12 23.1 1.9 3.2 2.2 2.7 1.9
13 12.9 0.9 1.9 0.9 0.8 1.3
14 17.5 1.7 17.3 5.7 5.3 2.1
15 8.9 1.0 1.7 1.0 2.0 1.0
16 11.9 2.4 4.0 1.5 3.74 2.9
17 8.3 1.8 10.7 3.2 1.2 2.0
18 37.2 1.6 6.8 1.4 1.9 0.8
19 23.2 1.6 5.6 2.8 5.4 2.7
Mean 16.7 3.3 7.0 3.3 4.8 5.0
SEM 2.3 1.4 1.5 0.7 1.6 2.0
SLM: salmeterol; PD20: provocative dose causing a 20% fall
in forced expiratory volume in one second; #: data used for
the coefficient of repeatability (excluded patients Nos. 1 and
10; see text).
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the treatment effect is +2.15 DD and the effect through
FEV1 is 0.035×18.4=0.65, hence 2.8 DD as found in
the study. After 20 h, the treatment effect is +0.82 and
the effect through FEV1 is 0.028×10.4=0.29 (hence the
real found protection of 1.1 DD). This means that only
23% (0.65/2.80×100%) of the afforded protection can
be explained by bronchodilation, and 77% by a direct
effect of salmeterol. After 20 h these values are 26 and
74%, respectively.
Discussion
This study shows that a single dose of salmeterol aff-
ords both bronchodilation and protection against UNDW
provocation up to 20 h in asthmatic patients who did
not use anti-inflammatory medication. Protection against
UNDW provocation beyond the period of bronchodila-
tion did not occur. In 11 of 17 patients, the inhibition
of bronchoconstriction to UNDW decreased significantly
between 10 and 20 h, at which time bronchodilation
persisted. However, protection was still more than 1 DD
after 20 h, and up to this time, only a maximum of 26%
of the protection could be explained by the bronchodi-
lating effect of salmeterol.
The duration of protection against UNDW challenge
was in line with the in vitro activity of salmeterol.
UNDW provocation is thought to be mediated by the
release of mast cell mediators [9, 10]. Salmeterol inhibits
the release of these mediators from sensitized human
lung fragments for more than 20 h [2]. In the present
study, a single dose of salmeterol afforded protection at
10 h of almost 3 DD, and, although the magnitude of
the protection weaned, protection was still more than 1
DD after 20 h. In this way, salmeterol showed, in vivo,
a relevant protection during the period of blocking medi-
ators in vitro [2].
In accordance with BOOTH et al. [19], no increase in
BHR after withdrawal of salmeterol was found in our
study. Thirty four hours after inhalation of salmeterol
(more than three times the half-life), no rebound BHR
to UNDW occurred, the PD20,UNDW being 0.12 DD
above placebo.
Salmeterol also induced bronchodilation for more
than 20 h, and protected against the early morning dip
10 h after inhalation. TWENTYMAN et al. [7] tested bron-
chodilation of a single dose of salmeterol up to 34 h,
but regular measurements were discontinued after 9.5
h. When starting measurements again after 32 h, sal-
meterol no longer afforded bronchodilation. In a group
of asthmatic patients with similar characteristics as in
the present study, RABE et al. [20] showed that salme-
terol decreased airway tone significantly over a whole
24 h period, compared with placebo. Because of multi-
ple comparisons, however, the bronchodilating effect
was not significant beyond 12 h at the individual time-
points. Our study clearly shows a bronchodilation up to
20 h, which disappeared after 34 h.
Besides bronchodilation, an important property of
salmeterol could be the ability to afford protection of
airways smooth muscle against bronchoconstrictor med-
iators with time-course characteristics different from
those observed for bronchodilation [7]. Since baseline
airway function correlates somewhat with airway reac-
tivity [18], the inhibitory effect of a bronchodilator could
be due to a change in airway calibre. In this study, both
bronchodilation and protection lasted more than 20 h
but less than 34 h. More measurements of UNDW provo-
cation during this period would be needed to determine
exactly the duration of action and to distinguish bet-
ween protection and bronchodilation. However, we made
measurements at 10 h intervals to avoid confounding
problems such as a temporary (small) increase in BHR
after UNDW provocation [10, 21], and to avoid refrac-
toriness after repeated UNDW measurements [14, 21],
which may persist up to 4 h after the last challenge [22,
23]. Despite this, two patients (subjects No. 2 (dropped
out) and 10) became refractory to successive UNDW
provocations.
No correlation was found between bronchodilation
(∆FEV1) and protection (∆PD20,UNDW) provided by sal-
meterol at any time-point, indicating that protection was
not caused by bronchodilation. However, the number of
patients in our study is probably too small to state that
there might not be a correlation with a much larger
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Fig. 1.  –  The change in FEV1 and corresponding PD20,UNDW points in each patient, from: a) 10–20 h; and b) 20–34 h after inhalation of sal-
meterol. ❏: 10 h; ■: 20 h; ∆: 34 h after inhalation of salmeterol. Mean (SEM) values of FEV1 and PD20,UNDW are shown at the corresponding
axes: *: p<0.05; **: p<0.01; ***: p<0.001; NS: nonsignificant. FEV1: forced expiratory volume in one second; PD20,UNDW: provocative dose of
ultrasonically nebulized distilled water causing a 20% fall of FEV1; % pred: percentage of predicted value.
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population. On the other hand, figure 1 shows that in
individual patients the protection afforded by salmeterol
is independent of airway calibre, and there were mod-
erate-to-severe responses to inhalation to water at a
time when airway calibre was optimal. The regression
lines through these points again show a highly signifi-
cant treatment effect of salmeterol, by shifting the lines
at 10 and 20 h parallel to higher levels than after place-
bo. From the equations of the regression lines on sal-
meterol and on placebo at the various time-points, it can
be calculated that up to 20 h, only a maximum of 26%
of the protection can be explained by the bronchodilat-
ing effect of salmeterol. Therefore, there seems to be a
differential effect of salmeterol on lung function and the
response to UNDW. A similar dissociation has been
shown with sodium cromoglycate, which had no effect
on lung function, but did block UNDW provocation
[24]. Conversely, ipratropium bromide in doses up to
160 µg caused bronchodilation, but did not change the
response to challenge with UNDW [25].
Other mechanisms are thus likely to be involved in
the protective effects of salmeterol against UNDW-in-
duced bronchoconstriction. The term functional antago-
nism is often used to describe the protective effects of
β2-agonists during provocation tests. β2-agonists may
prevent smooth muscle contraction, irrespective of the
constrictor mediator, by acting on a different receptor
on the same cell, which opposes this constriction [26].
In this way, pharmacological effects of β2-agonists are
different between smooth muscle relaxation and pro-
tection against bronchoconstriction [27]. It has previ-
ously been shown that β2-agonists provide true functional
antagonistic protection at the level of the smooth mus-
cle against direct pharmacological stimuli as histamine
and methacholine [28]. UNDW, however, is thought not
to act directly at the level of the smooth muscle, but to
induce airway narrowing indirectly [9, 10]. Therefore,
mechanisms other than bronchodilation and functional
antagonism should be considered to explain this appar-
ent dissociation.
O'CONNOR et al. [29] showed that β2-agonists have an
additional inhibitory nonsmooth muscle effect on bron-
choconstrictor stimuli that involve mast cell activation,
in affording a greater protection against adenosine mono-
phosphate- than methacholine-induced bronchoconstri-
ction. Salmeterol has several acute anti-inflammatory
effects in vitro that may contribute, e.g. the strong inhi-
bition of the release of mast cell mediators [2], involved
in the mechanism of action of UNDW. Thus, although
the evidence is only indirect, this protection may indi-
cate long-lasting cell-stabilizing effects of salmeterol in
vivo up to 20 h rather than functional antagonism.
Finally, in a number of patients, the protection of sal-
meterol against UNDW decreased, while bronchodila-
tion persisted. This dichotomy between duration of
bronchodilation and protection against a bronchocon-
strictor stimulus has already been described by AHRENS
et al. [30]. These differences in time course could reflect
differences in the mechanism for these two β2-agonis-
tic actions. However, an alternative explanation could
be the differences in potency of the bronchoconstrictor
stimulus. A larger concentration of a β2-agonist may be
required to prevent contraction to a potent stimulus as
a provocation test, as compared with the concentration
of the drug to produce relaxation of the relatively mod-
est level of bronchospasm at baseline [31]. Several stud-
ies showed a relationship between bronchodilator dose
and the degree of inhibition of provocation [32]. A
greater concentration of salmeterol may be required to
prevent contraction to UNDW provocation than is required
to produce relaxation. However, the concentration of
salmeterol required to prevent mast cell mediator release
may similarly be higher than the concentration required
to prevent contraction of the muscle by the mediators
released.
Whether this nonbronchodilator effect of salmeterol
also provides clinically relevant effects or persists after
prolonged therapy, is at present unclear. No change in
BHR was reported after 6 weeks of treatment with sal-
meterol [7]. On the other hand, salmeterol significantly
improved the treatment of (chronic) bronchial asthma
and resulted in a clinical significant improvement in qual-
ity of life versus placebo and salbutamol [33]. GREENING
et al. [34] showed that adding salmeterol to inhaled cor-
ticosteroid therapy was more appropriate for patients
with inadequately controlled asthma on low-dose inhaled
corticosteroids than doubling this dose. Finally, in this
study, salmeterol afforded a significant protection of
more than 20 h against a naturally occurring stimulus,
which may be very relevant for asthma management.
In conclusion, our study shows that a single dose of
salmeterol in mild-to-moderate asthma causes bron-
chodilation and protection independently of this bron-
chodilation against a physiological bronchoconstrictor
stimulus for more than 20 h.
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